The story of Viagra presents a complex picture for investors. While the initial launch generated significant gains, the end of its exclusive rights opened the avenue to off-brand competitors, dramatically eroding market share. This creates a unique dilemma for drug manufacturers depending on comparable blockbuster medications, suggesting that a car

The legacy of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in revenue , its patent expiration created a wave of generic competition , significantly impacting its market share . While some businesses may attempt to capitalize on related treatments , the existing